Diagnostic Role of Circulating Endocan Levels in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.

IF 2.6 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Angiology Pub Date : 2024-07-01 Epub Date: 2023-06-08 DOI:10.1177/00033197231183087

Amir Hossein Behnoush, Amirmohammad Khalaji, Nikan Amirkhani, Parmida Sadat Pezeshki

{"title":"Diagnostic Role of Circulating Endocan Levels in Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis.","authors":"Amir Hossein Behnoush, Amirmohammad Khalaji, Nikan Amirkhani, Parmida Sadat Pezeshki","doi":"10.1177/00033197231183087","DOIUrl":null,"url":null,"abstract":"<p><p>Endocan, as an endothelial cell damage marker, plays role in several cardiovascular and non-cardiovascular diseases. This systematic review and meta-analysis evaluates the role of endocan as a potential diagnostic or prognostic biomarker for obstructive sleep apnea (OSA). International databases including PubMed, Embase, Web of Science, and Scopus were searched for relevant studies assessing endocan levels in OSA patients compared with healthy controls or within different severities or comorbidities of OSA. Random-effect meta-analysis was performed in order to calculate the standardized mean difference (SMD) and 95% confidence interval (CI) of serum/plasma endocan in all comparisons. A total of 10 studies were included in our systematic review, among which seven were used in meta-analysis. Meta-analysis showed that endocan levels were significantly higher in patients with OSA compared with healthy controls (SMD 1.29, 95% CI 0.64-1.93, P < .001) and this was not different between serum and plasma subgroups. However, there was no statistical difference between severe and non-severe OSA patients (SMD .64, 95% CI -.22 to 1.50, P = .147). Considerably, higher endocan levels in patients with OSA in comparison with non-OSA individuals might have clinical implications. This association warrants further research due to its potential use as a diagnostic and prognostic biomarker.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197231183087","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/6/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Endocan, as an endothelial cell damage marker, plays role in several cardiovascular and non-cardiovascular diseases. This systematic review and meta-analysis evaluates the role of endocan as a potential diagnostic or prognostic biomarker for obstructive sleep apnea (OSA). International databases including PubMed, Embase, Web of Science, and Scopus were searched for relevant studies assessing endocan levels in OSA patients compared with healthy controls or within different severities or comorbidities of OSA. Random-effect meta-analysis was performed in order to calculate the standardized mean difference (SMD) and 95% confidence interval (CI) of serum/plasma endocan in all comparisons. A total of 10 studies were included in our systematic review, among which seven were used in meta-analysis. Meta-analysis showed that endocan levels were significantly higher in patients with OSA compared with healthy controls (SMD 1.29, 95% CI 0.64-1.93, P < .001) and this was not different between serum and plasma subgroups. However, there was no statistical difference between severe and non-severe OSA patients (SMD .64, 95% CI -.22 to 1.50, P = .147). Considerably, higher endocan levels in patients with OSA in comparison with non-OSA individuals might have clinical implications. This association warrants further research due to its potential use as a diagnostic and prognostic biomarker.

查看原文本刊更多论文

循环内皮素水平在阻塞性睡眠呼吸暂停中的诊断作用：系统回顾与元分析》。

内皮细胞损伤标志物内皮细胞损伤素在多种心血管和非心血管疾病中发挥作用。本系统综述和荟萃分析评估了内皮细胞损伤蛋白作为阻塞性睡眠呼吸暂停（OSA）潜在诊断或预后生物标志物的作用。在包括PubMed、Embase、Web of Science和Scopus在内的国际数据库中搜索了评估OSA患者与健康对照组或不同严重程度或合并症的OSA患者体内内皮素水平的相关研究。为了计算所有比较中血清/血浆内切酶的标准化平均差（SMD）和95%置信区间（CI），进行了随机效应荟萃分析。我们的系统综述共纳入了 10 项研究，其中 7 项用于荟萃分析。荟萃分析表明，与健康对照组相比，OSA 患者的内切酶水平明显较高（SMD 1.29，95% CI 0.64-1.93，P < .001），且血清和血浆亚组之间没有差异。然而，严重和非严重 OSA 患者之间没有统计学差异（SMD .64，95% CI -.22 至 1.50，P = .147）。值得注意的是，与非 OSA 患者相比，OSA 患者体内更高的内切酶水平可能会产生临床影响。这种关联值得进一步研究，因为它有可能被用作诊断和预后的生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Angiology 医学-外周血管病

CiteScore

5.50

自引率

14.30%

发文量

180

审稿时长

6-12 weeks

期刊介绍： A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days